Cargando…
Non-profit drug research and development: the case study of Genethon
Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249613/ https://www.ncbi.nlm.nih.gov/pubmed/30479703 http://dx.doi.org/10.1080/20016689.2018.1545514 |
_version_ | 1783372783344943104 |
---|---|
author | Jarosławski, Szymon Toumi, Mondher |
author_facet | Jarosławski, Szymon Toumi, Mondher |
author_sort | Jarosławski, Szymon |
collection | PubMed |
description | Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms. Like other non-profits, Genethon is willing to adopt an ethical attitude toward their donors by pricing their products affordably. It remains to be seen if the approach to internalize the marketing authorization, manufacturing and distribution activities prove to be efficient and sustainable. Also, the firm faces an ethical dilemma because lower prices of innovative drugs can dry the for-profit R&D in the area and prevent patient access to future innovations. |
format | Online Article Text |
id | pubmed-6249613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Routledge |
record_format | MEDLINE/PubMed |
spelling | pubmed-62496132018-11-26 Non-profit drug research and development: the case study of Genethon Jarosławski, Szymon Toumi, Mondher J Mark Access Health Policy Short Communication Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms. Like other non-profits, Genethon is willing to adopt an ethical attitude toward their donors by pricing their products affordably. It remains to be seen if the approach to internalize the marketing authorization, manufacturing and distribution activities prove to be efficient and sustainable. Also, the firm faces an ethical dilemma because lower prices of innovative drugs can dry the for-profit R&D in the area and prevent patient access to future innovations. Routledge 2018-11-15 /pmc/articles/PMC6249613/ /pubmed/30479703 http://dx.doi.org/10.1080/20016689.2018.1545514 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Jarosławski, Szymon Toumi, Mondher Non-profit drug research and development: the case study of Genethon |
title | Non-profit drug research and development: the case study of Genethon |
title_full | Non-profit drug research and development: the case study of Genethon |
title_fullStr | Non-profit drug research and development: the case study of Genethon |
title_full_unstemmed | Non-profit drug research and development: the case study of Genethon |
title_short | Non-profit drug research and development: the case study of Genethon |
title_sort | non-profit drug research and development: the case study of genethon |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249613/ https://www.ncbi.nlm.nih.gov/pubmed/30479703 http://dx.doi.org/10.1080/20016689.2018.1545514 |
work_keys_str_mv | AT jarosławskiszymon nonprofitdrugresearchanddevelopmentthecasestudyofgenethon AT toumimondher nonprofitdrugresearchanddevelopmentthecasestudyofgenethon |